Australia markets open in 40 minutes

Vectus Biosystems Limited (VBS.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.25000.0000 (0.00%)
At close: 03:15PM AEST

Vectus Biosystems Limited

11 Julius Avenue
Level 3
North Ryde, NSW 2113
Australia
61 2 8876 8200
https://www.vectusbiosystems.com.au

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Karen Annette DugganCEO & Executive Director255.75kN/AN/A
Mr. Robert John Waring BEc, CA, FAICD, FCIS, FFinCompany SecretaryN/AN/AN/A
Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D.Consultant10.83kN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; and VB4-A79 for the treatment of lung fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in North Ryde, Australia.

Corporate governance

Vectus Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.